Full text is available at the source.
Abstract
In a phase 3 trial involving 320 participants, mazdutide 6 mg reduced HbA1c by 2.15% at 24 weeks compared to a 0.14% reduction with placebo.
- Mazdutide monotherapy significantly improved glycaemic control compared to placebo, with treatment differences of -1.43% for 4 mg and -2.02% for 6 mg.
- Participants receiving mazdutide experienced significant weight loss, averaging -5.61% for 4 mg and -7.81% for 6 mg, compared to -1.26% for placebo.
- More participants on mazdutide achieved clinically relevant HbA1c targets (<7.0%) and weight loss goals (≥5%) compared to those on placebo.
- The most common adverse events included diarrhoea, decreased appetite, and nausea, aligning with the profile of GLP-1 receptor agonists.
- Mazdutide may offer an effective treatment option for adults with type 2 diabetes inadequately controlled by diet and exercise alone.
Simplified